Vulvovaginal candidiasis
diseaseOn this page
Also known as candidal vulvovaginitiscandidal: [vulvovaginitis NOS] or [cervix]candidal: cervixcandidiasis of vulva and vaginamonilial vulvovaginitisvaginal candidiasis
Summary
Vulvovaginal candidiasis (MONDO:0006014) is a disease and 67 clinical trials. Top therapeutic interventions include fluconazole, clotrimazole, and miconazole. A subtype of cutaneous candidiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 67
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | vulvovaginal candidiasis |
| Mondo ID | MONDO:0006014 |
| EFO | EFO:0007543 |
| MeSH | D002181 |
| DOID | DOID:2272 |
| ICD-10-CM | B37.3 |
| NCIT | C2914 |
| SNOMED CT | 72605008 |
| UMLS | C0700345 |
| MedGen | 195979 |
| Is cancer (heuristic) | no |
Also known as: candidal vulvovaginitis · candidal: [vulvovaginitis NOS] or [cervix] · candidal: cervix · candidiasis of vulva and vagina · monilial vulvovaginitis · vaginal candidiasis · vulvovaginal candidiasis
Disease family
This is a subtype of cutaneous candidiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › opportunistic mycosis › candidiasis › cutaneous candidiasis › vulvovaginal candidiasis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 8 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Fluconazole | Approved (phase 4) |
| Oteseconazole | Approved (phase 4) |
| Amphotericin B | Phase 3 (in late-stage trials) |
| Boric Acid | Phase 3 (in late-stage trials) |
| Clindamycin | Phase 3 (in late-stage trials) |
| Clotrimazole | Phase 3 (in late-stage trials) |
| Ibrexafungerp | Phase 3 (in late-stage trials) |
| Ketoconazole | Phase 3 (in late-stage trials) |
| Terconazole | Phase 3 (in late-stage trials) |
| Tetracycline | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 67.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 27 |
| PHASE3 | 15 |
| PHASE2 | 7 |
| PHASE4 | 5 |
| PHASE2/PHASE3 | 4 |
| PHASE1/PHASE2 | 4 |
| PHASE1 | 3 |
| EARLY_PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00194324 | PHASE4 | COMPLETED | Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina |
| NCT02180100 | PHASE4 | COMPLETED | Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis |
| NCT02242695 | PHASE4 | COMPLETED | Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis |
| NCT03839875 | PHASE4 | COMPLETED | Evaluation of Efficacy and Safety of Gynomax® XL Ovule |
| NCT04699240 | PHASE4 | COMPLETED | Study of Lactobacillus in Adjuvant Treatment of RVVC |
| NCT06474247 | PHASE2/PHASE3 | RECRUITING | Postbiotic as Adjunct Treatment for Vaginal Candidiasis |
| NCT06835361 | PHASE2/PHASE3 | RECRUITING | Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis |
| NCT07109869 | PHASE3 | RECRUITING | Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis |
| NCT00353561 | PHASE3 | COMPLETED | Diabetes Mellitus and Vulvovaginal Candidiasis |
| NCT00755053 | PHASE3 | COMPLETED | Comparative Efficacy of Ovule vs Tablet |
| NCT01806623 | PHASE3 | COMPLETED | The Study Of Fluconazole For Vulvovaginal Candidiasis |
| NCT02907307 | PHASE3 | WITHDRAWN | Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis |
| NCT03059992 | PHASE3 | COMPLETED | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment |
| NCT03115073 | PHASE2/PHASE3 | COMPLETED | ProF-001_Phase IIa |
| NCT03473418 | PHASE3 | UNKNOWN | Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis |
| NCT03561701 | PHASE3 | COMPLETED | A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) |
| NCT03562156 | PHASE3 | COMPLETED | A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) |
| NCT03840616 | PHASE3 | COMPLETED | Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections |
| NCT04029116 | PHASE3 | COMPLETED | Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) |
| NCT04734405 | PHASE2/PHASE3 | UNKNOWN | A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) |
| NCT04956419 | PHASE3 | UNKNOWN | A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis |
| NCT05074602 | PHASE3 | UNKNOWN | A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis |
| NCT05399641 | PHASE3 | COMPLETED | Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis |
| NCT06056947 | PHASE3 | COMPLETED | Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule |
| NCT06190509 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study |
| NCT06450990 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection |
| NCT01144286 | PHASE2 | COMPLETED | Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment |
| NCT01497223 | PHASE2 | COMPLETED | MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis |
| NCT01926028 | PHASE1/PHASE2 | COMPLETED | Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis |
| NCT02267382 | PHASE2 | COMPLETED | A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) |
| NCT02679456 | PHASE2 | COMPLETED | Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis |
| NCT02866227 | PHASE2 | COMPLETED | TOL-463 Phase 2 Study for Vaginitis |
| NCT03024502 | PHASE1/PHASE2 | UNKNOWN | Patients With Vulvovaginal Candidiasis |
| NCT04813822 | PHASE2 | UNKNOWN | Study Evaluating the Efficacy and Safety of Miconazole Nitrate + Domiphen Bromide Vaginal Cream in the Treatment of Subjects With Acute Vulvovaginal Candidiasis |
| NCT05031481 | PHASE2 | WITHDRAWN | Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis. |
| NCT00479947 | PHASE1 | UNKNOWN | Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis |
| NCT01067131 | PHASE1 | COMPLETED | Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection |
| NCT06954493 | PHASE1 | COMPLETED | Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp |
| NCT05753813 | EARLY_PHASE1 | RECRUITING | Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome |
| NCT02150655 | EARLY_PHASE1 | COMPLETED | Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUCONAZOLE | 4 | 8 |
| CLOTRIMAZOLE | 4 | 6 |
| MICONAZOLE | 4 | 6 |
| IBREXAFUNGERP | 4 | 5 |
| OTESECONAZOLE | 4 | 3 |
| BUTOCONAZOLE NITRATE | 4 | 2 |
| DEQUALINIUM CHLORIDE | 4 | 1 |
| KETOCONAZOLE | 4 | 1 |
| LACTULOSE | 4 | 1 |
| LEVOKETOCONAZOLE | 4 | 1 |
| TERCONAZOLE | 4 | 1 |
| BORIC ACID | 3 | 1 |
| NITRIC ACID | 3 | 1 |
| NUX VOMICA EXTRACT | 3 | 1 |
| PYRROLE | 3 | 1 |
| ARASERTACONAZOLE | 2 | 1 |
| CHEMBL4764856 | 0 | 4 |
| CHEMBL328863 | 0 | 1 |
| CHEMBL75 | 0 | 1 |
| CHEMBL186200 | 0 | 1 |